- NEWS AND VIEWS
Insights into the origins of pancreatic cancer
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Nature 597, 641-642 (2021)
doi: https://doi.org/10.1038/d41586-021-02435-4
References
Grimont, A., Leach, S. D. & Chadwani, R. Cell. Mol. Gastroenterol. Hepatol. https://doi.org/10.1016/j.jcmgh.2021.07.014 (2021).
Neuhöfer, P. et al. Nature 597, 715–719 (2021).
Fischer, C. G. & Wood, L. D. J. Pathol. 246, 395–404 (2018).
Kipling, D. & Cooke, H. J. Nature 347, 400–402 (1990).
van Heek, N. T. et al. Am. J. Pathol. 161, 1541–1547 (2002).
Competing Interests
A.M. receives royalties for a pancreatic cancer biomarker test from Cosmos Wisdom Biotechnology, and this financial relationship is managed and monitored by the UTMDACC Conflict of Interest Committee. A.M. also receives royalties as an inventor on a patent that has been licensed by Johns Hopkins University to Thrive Earlier Detection (an Exact Sciences Company). A.M. serves as a consultant for Freenome.